{"id":742287,"date":"2013-11-09T12:00:00","date_gmt":"2013-11-09T12:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-grass-sublingual-allergy-immunotherapy-tablet-significantly-reduced-allergy-symptoms-and-need-for-symptom-relief-medication-in-adults-and-children-in-pivotal-phase-iii\/"},"modified":"2023-03-22T00:04:32","modified_gmt":"2023-03-22T04:04:32","slug":"mercks-investigational-grass-sublingual-allergy-immunotherapy-tablet-significantly-reduced-allergy-symptoms-and-need-for-symptom-relief-medication-in-adults-and-children-in-pivotal-phase-iii","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-grass-sublingual-allergy-immunotherapy-tablet-significantly-reduced-allergy-symptoms-and-need-for-symptom-relief-medication-in-adults-and-children-in-pivotal-phase-iii\/","title":{"rendered":"Merck\u2019s Investigational Grass Sublingual Allergy Immunotherapy Tablet Significantly Reduced Allergy Symptoms and Need for Symptom-Relief Medication in Adults and Children in Pivotal Phase III Study"},"content":{"rendered":"<p class=\"bwalignc\">       Data to be Presented at the American College of Allergy, Asthma &amp;        Immunology Annual Scientific Meeting     <\/p>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced data for its investigational Timothy grass sublingual<br \/>\n      allergy immunotherapy tablet (MK-7243) from a study involving 1,501<br \/>\n      North American adult and pediatric patients. Results showed that MK-7243<br \/>\n      demonstrated significant improvement in Total Combined Score (TCS)<br \/>\n      averaged over the entire grass pollen season (the primary endpoint),<br \/>\n      which was the sum of the rhinoconjunctivitis daily symptom score (DSS)<br \/>\n      and the daily medication score (DMS), compared to placebo. Researchers<br \/>\n      will present findings at the American College of Allergy, Asthma &amp;<br \/>\n      Immunology Annual Scientific Meeting, Nov. 7-11, in Baltimore.\n    <\/p>\n<p>\n      \u201cPatients in this study who took the investigational Timothy grass<br \/>\n      sublingual allergy immunotherapy tablet showed a significant improvement<br \/>\n      in common allergy symptoms during the entire grass season,\u201d said Dr.<br \/>\n      David Bernstein, professor of Medicine and Environmental Health,<br \/>\n      Division of Immunology, Allergy and Rheumatology, University of<br \/>\n      Cincinnati College of Medicine, who was one of the study investigators.\n    <\/p>\n<p>\n      \u201cFew large studies have evaluated sublingual immunotherapy for allergic<br \/>\n      rhinitis in both adults and children, and we are proud that Merck is<br \/>\n      exploring this potential new option for Timothy grass pollen-induced<br \/>\n      allergic rhinitis treatment in North America,\u201d said Dr. Sean Curtis,<br \/>\n      vice president, Respiratory and Immunology, Merck Research Laboratories.\n    <\/p>\n<p>\n      <b>Study design<\/b>\n    <\/p>\n<p>\n      This multicenter, double-blind, randomized, placebo-controlled,<br \/>\n      parallel-group study evaluated the efficacy and safety of the<br \/>\n      investigational MK-7243 sublingual tablet (2800 BAU) in 1,501 pediatric<br \/>\n      and adult patients (ages 5-65) with a clinical history of Timothy grass<br \/>\n      pollen-induced allergic rhinitis with or without conjunctivitis, with or<br \/>\n      without asthma (FEV<sub>1<\/sub> \u226570 percent of predicted value). As<br \/>\n      baseline characteristics, 25 percent of patients in the study had<br \/>\n      asthma; patients with a history of severe asthma were excluded.<br \/>\n      Additionally, 85 percent of patients in the study were sensitized to<br \/>\n      multiple allergens. Patients received either MK-7243 or placebo once<br \/>\n      daily for at least 12 weeks prior to and during the grass pollen season.\n    <\/p>\n<p>\n      The primary efficacy assessment of the study was total combined score<br \/>\n      (TCS), which was the sum of the rhinoconjunctivitis daily symptom score<br \/>\n      (DSS) and the daily medication score (DMS) averaged over the entire<br \/>\n      grass pollen season. The DSS consisted of daily ratings of four nasal<br \/>\n      symptoms (runny nose, blocked nose, sneezing and itchy nose) and two eye<br \/>\n      symptoms (gritty eyes and watery eyes) on a scale from zero (no<br \/>\n      symptoms) to three (severe symptoms). The DMS was based on the type and<br \/>\n      amount of allergy rescue medication (oral antihistamines, ocular<br \/>\n      antihistamines, intranasal corticosteroids or oral corticosteroids) used<br \/>\n      each day during the grass pollen season, which patients in both arms of<br \/>\n      the study were permitted to use.\n    <\/p>\n<p>\n      Four key secondary endpoints included the average rhinoconjunctivitis<br \/>\n      DSS over the entire grass pollen season, the average rhinoconjunctivitis<br \/>\n      DMS over the entire grass pollen season, the average rhinoconjunctivitis<br \/>\n      TCS over the peak grass season, and the average overall score for the<br \/>\n      Rhinoconjunctivitis Quality of Life Questionnaire with Standardized<br \/>\n      Activities for Subjects \u226512 Years of Age (RQLQ(S)12+) over the peak<br \/>\n      grass pollen season. Safety endpoints included reported adverse events.\n    <\/p>\n<p>\n      <b>Study results<\/b>\n    <\/p>\n<p>\n      In this study, patients treated with MK-7243 (n=629) showed a 23 percent<br \/>\n      improvement in TCS relative to placebo (n=672) over the entire grass<br \/>\n      pollen season (median difference: -0.98, P &lt; .001). Additionally,<br \/>\n      patients treated with MK-7243 demonstrated a 20 percent improvement in<br \/>\n      DSS over the entire grass pollen season (median difference: -0.64, P<br \/>\n      =.001), and a 35 percent improvement in DMS over the entire grass pollen<br \/>\n      season (mean difference: -0.48, P&lt;.001). During the peak grass pollen<br \/>\n      season, patients treated with MK-7243 demonstrated a 29 percent<br \/>\n      improvement in TCS (median difference: 1.33, P&lt;.001), and a 12 percent<br \/>\n      improvement in RQLQ (median difference: -0.13, P=.027).\n    <\/p>\n<p>\n      The most frequently reported adverse events in the study for MK-7243<br \/>\n      (n=753) versus placebo (n=745) were local site reactions: throat<br \/>\n      irritation 23 percent vs. 4 percent, oral pruritus 19 percent vs. 3<br \/>\n      percent, oral paraesthesia 12 percent vs. 3 percent, mouth edema 13<br \/>\n      percent vs. 1 percent and ear pruritus 12 percent vs. 1 percent,<br \/>\n      respectively. No serious treatment-related adverse events were reported.<br \/>\n      Three patients (2 MK-7243, 1 placebo) had moderate systemic allergic<br \/>\n      reactions. Symptoms resolved without treatment for the two patients who<br \/>\n      received MK-7243, and both of these patients discontinued treatment.<br \/>\n      Four different patients (3 MK-7243, 1 placebo) were administered<br \/>\n      epinephrine. Two of the four epinephrine administrations (1 MK-7243, 1<br \/>\n      placebo) were reported as unrelated to the study medication. Of the<br \/>\n      remaining two administrations for patients who received MK-7243, one was<br \/>\n      deemed possibly related to the study medication and the other was deemed<br \/>\n      probably related.\n    <\/p>\n<p>\n      These results reflect data from the full analysis set, which included<br \/>\n      randomized patients who took at least one dose of study medication and<br \/>\n      had at least one efficacy measurement in the corresponding evaluation<br \/>\n      period (entire grass pollen season or peak grass pollen season).\n    <\/p>\n<p>\n      These results will be presented in a poster titled \u201cEfficacy and Safety<br \/>\n      of MK-7243: A Grass Sublingual Immunotherapy Tablet Treatment in a Large<br \/>\n      Randomized Controlled Trial in North American Children and Adults\u201d on<br \/>\n      Saturday, Nov. 9 from 12:30 \u2013 1:30 p.m. ET and Sunday, Nov. 10 from<br \/>\n      12:30 \u2013 1:30 p.m. ET.\n    <\/p>\n<p>\n      In addition, a pre-specified sub-group analysis of the data from this<br \/>\n      clinical trial will be presented in a poster titled \u201cTreatment with<br \/>\n      MK-7243, a Grass Sublingual Immunotherapy Tablet, is Associated with<br \/>\n      Similar Efficacy and Safety in Children and Adults: Findings from a<br \/>\n      Subgroup Analysis of Data from a Large North American Trial\u201d on<br \/>\n      Saturday, Nov. 9 from 12:30 \u2013 1:30 p.m. ET and Sunday, Nov. 10 from<br \/>\n      12:30 \u2013 1:30 p.m. ET.\n    <\/p>\n<p>\n      <b>Merck&#8217;s investigational sublingual allergy immunotherapy tablet<br \/>\n      program<\/b>\n    <\/p>\n<p>\n      Merck&#8217;s Timothy grass sublingual allergy immunotherapy tablet is an<br \/>\n      investigational once-daily tablet that dissolves under the tongue and is<br \/>\n      designed to help treat the underlying cause of allergic rhinitis by<br \/>\n      generating an immune response to help protect patients against Timothy<br \/>\n      grass pollen.\n    <\/p>\n<p>\n      Earlier this year, Merck announced that the U.S. Food and Drug<br \/>\n      Administration (FDA) had accepted for review Biologics License<br \/>\n      Applications for its investigational Timothy grass sublingual allergy<br \/>\n      immunotherapy tablet and its ragweed sublingual allergy immunotherapy<br \/>\n      tablet. Merck expects the FDA\u2019s review for both to be completed in the<br \/>\n      first half of 2014. Merck has partnered with ALK-Abello to develop its<br \/>\n      sublingual allergy immunotherapy tablets for Timothy grass pollen,<br \/>\n      ragweed pollen and house dust mite induced allergic rhinitis in North<br \/>\n      America.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=50747711&amp;newsitemid=20131109005037&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=1&amp;md5=55473360ea3bb82d62e4dc2c6c62fddb\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.twitter%2FMerck&amp;esheet=50747711&amp;newsitemid=20131109005037&amp;lan=en-US&amp;anchor=Twitter&amp;index=2&amp;md5=5eaaa8204713c7f53d74d28540248104\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=50747711&amp;newsitemid=20131109005037&amp;lan=en-US&amp;anchor=Facebook&amp;index=3&amp;md5=b2d9dc7058c3fdb8dd6ab3006486ca75\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=50747711&amp;newsitemid=20131109005037&amp;lan=en-US&amp;anchor=YouTube&amp;index=4&amp;md5=87448df1594f9e4bbbb6506fae3627d8\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2012 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50747711&amp;newsitemid=20131109005037&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=5&amp;md5=948a5605c12b91500d3f2e3708b9f999\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20131109005037r1&amp;sid=hq1sf1&amp;distro=nx\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       For Merck<br \/>Media:<br \/>Pam Eisele, 908-423-5042<br \/>or<br \/>Robert        Consalvo, 908-423-6595<br \/>or<br \/>Investors:<br \/>Carol Ferguson,        908-423-4465<br \/>or<br \/>Justin Holko, 908-423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Data to be Presented at the American College of Allergy, Asthma &amp; Immunology Annual Scientific Meeting Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced data for its investigational Timothy grass sublingual allergy immunotherapy tablet (MK-7243) from a study involving 1,501 North American adult and pediatric patients. Results showed that MK-7243 demonstrated significant improvement in Total Combined Score (TCS) averaged over the entire grass pollen season (the primary endpoint), which was the sum of the rhinoconjunctivitis daily symptom score (DSS) and the daily medication score (DMS), compared to placebo. Researchers will present findings at the American College of Allergy, Asthma &amp; Immunology Annual Scientific Meeting, Nov. 7-11, in Baltimore. \u201cPatients in this study who took the investigational Timothy grass sublingual allergy immunotherapy tablet showed a significant improvement in common allergy symptoms during the entire grass season,\u201d<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-742287","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck\u2019s Investigational Grass Sublingual Allergy Immunotherapy Tablet Significantly Reduced Allergy Symptoms and Need for Symptom-Relief Medication in Adults and Children in Pivotal Phase III Study - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-grass-sublingual-allergy-immunotherapy-tablet-significantly-reduced-allergy-symptoms-and-need-for-symptom-relief-medication-in-adults-and-children-in-pivotal-phase-iii\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck\u2019s Investigational Grass Sublingual Allergy Immunotherapy Tablet Significantly Reduced Allergy Symptoms and Need for Symptom-Relief Medication in Adults and Children in Pivotal Phase III Study - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Data to be Presented at the American College of Allergy, Asthma &amp; Immunology Annual Scientific Meeting Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced data for its investigational Timothy grass sublingual allergy immunotherapy tablet (MK-7243) from a study involving 1,501 North American adult and pediatric patients. Results showed that MK-7243 demonstrated significant improvement in Total Combined Score (TCS) averaged over the entire grass pollen season (the primary endpoint), which was the sum of the rhinoconjunctivitis daily symptom score (DSS) and the daily medication score (DMS), compared to placebo. Researchers will present findings at the American College of Allergy, Asthma &amp; Immunology Annual Scientific Meeting, Nov. 7-11, in Baltimore. \u201cPatients in this study who took the investigational Timothy grass sublingual allergy immunotherapy tablet showed a significant improvement in common allergy symptoms during the entire grass season,\u201d\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-grass-sublingual-allergy-immunotherapy-tablet-significantly-reduced-allergy-symptoms-and-need-for-symptom-relief-medication-in-adults-and-children-in-pivotal-phase-iii\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:32+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20131109005037r1&amp;sid=hq1sf1&amp;distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-grass-sublingual-allergy-immunotherapy-tablet-significantly-reduced-allergy-symptoms-and-need-for-symptom-relief-medication-in-adults-and-children-in-pivotal-phase-iii\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-grass-sublingual-allergy-immunotherapy-tablet-significantly-reduced-allergy-symptoms-and-need-for-symptom-relief-medication-in-adults-and-children-in-pivotal-phase-iii\\\/\",\"name\":\"Merck\u2019s Investigational Grass Sublingual Allergy Immunotherapy Tablet Significantly Reduced Allergy Symptoms and Need for Symptom-Relief Medication in Adults and Children in Pivotal Phase III Study - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-grass-sublingual-allergy-immunotherapy-tablet-significantly-reduced-allergy-symptoms-and-need-for-symptom-relief-medication-in-adults-and-children-in-pivotal-phase-iii\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-grass-sublingual-allergy-immunotherapy-tablet-significantly-reduced-allergy-symptoms-and-need-for-symptom-relief-medication-in-adults-and-children-in-pivotal-phase-iii\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20131109005037r1&amp;sid=hq1sf1&amp;distro=nx\",\"datePublished\":\"2013-11-09T12:00:00+00:00\",\"dateModified\":\"2023-03-22T04:04:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-grass-sublingual-allergy-immunotherapy-tablet-significantly-reduced-allergy-symptoms-and-need-for-symptom-relief-medication-in-adults-and-children-in-pivotal-phase-iii\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-grass-sublingual-allergy-immunotherapy-tablet-significantly-reduced-allergy-symptoms-and-need-for-symptom-relief-medication-in-adults-and-children-in-pivotal-phase-iii\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-grass-sublingual-allergy-immunotherapy-tablet-significantly-reduced-allergy-symptoms-and-need-for-symptom-relief-medication-in-adults-and-children-in-pivotal-phase-iii\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20131109005037r1&amp;sid=hq1sf1&amp;distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20131109005037r1&amp;sid=hq1sf1&amp;distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-grass-sublingual-allergy-immunotherapy-tablet-significantly-reduced-allergy-symptoms-and-need-for-symptom-relief-medication-in-adults-and-children-in-pivotal-phase-iii\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck\u2019s Investigational Grass Sublingual Allergy Immunotherapy Tablet Significantly Reduced Allergy Symptoms and Need for Symptom-Relief Medication in Adults and Children in Pivotal Phase III Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck\u2019s Investigational Grass Sublingual Allergy Immunotherapy Tablet Significantly Reduced Allergy Symptoms and Need for Symptom-Relief Medication in Adults and Children in Pivotal Phase III Study - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-grass-sublingual-allergy-immunotherapy-tablet-significantly-reduced-allergy-symptoms-and-need-for-symptom-relief-medication-in-adults-and-children-in-pivotal-phase-iii\/","og_locale":"en_US","og_type":"article","og_title":"Merck\u2019s Investigational Grass Sublingual Allergy Immunotherapy Tablet Significantly Reduced Allergy Symptoms and Need for Symptom-Relief Medication in Adults and Children in Pivotal Phase III Study - Merck.com","og_description":"Data to be Presented at the American College of Allergy, Asthma &amp; Immunology Annual Scientific Meeting Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced data for its investigational Timothy grass sublingual allergy immunotherapy tablet (MK-7243) from a study involving 1,501 North American adult and pediatric patients. Results showed that MK-7243 demonstrated significant improvement in Total Combined Score (TCS) averaged over the entire grass pollen season (the primary endpoint), which was the sum of the rhinoconjunctivitis daily symptom score (DSS) and the daily medication score (DMS), compared to placebo. Researchers will present findings at the American College of Allergy, Asthma &amp; Immunology Annual Scientific Meeting, Nov. 7-11, in Baltimore. \u201cPatients in this study who took the investigational Timothy grass sublingual allergy immunotherapy tablet showed a significant improvement in common allergy symptoms during the entire grass season,\u201d","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-grass-sublingual-allergy-immunotherapy-tablet-significantly-reduced-allergy-symptoms-and-need-for-symptom-relief-medication-in-adults-and-children-in-pivotal-phase-iii\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:32+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20131109005037r1&amp;sid=hq1sf1&amp;distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-grass-sublingual-allergy-immunotherapy-tablet-significantly-reduced-allergy-symptoms-and-need-for-symptom-relief-medication-in-adults-and-children-in-pivotal-phase-iii\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-grass-sublingual-allergy-immunotherapy-tablet-significantly-reduced-allergy-symptoms-and-need-for-symptom-relief-medication-in-adults-and-children-in-pivotal-phase-iii\/","name":"Merck\u2019s Investigational Grass Sublingual Allergy Immunotherapy Tablet Significantly Reduced Allergy Symptoms and Need for Symptom-Relief Medication in Adults and Children in Pivotal Phase III Study - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-grass-sublingual-allergy-immunotherapy-tablet-significantly-reduced-allergy-symptoms-and-need-for-symptom-relief-medication-in-adults-and-children-in-pivotal-phase-iii\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-grass-sublingual-allergy-immunotherapy-tablet-significantly-reduced-allergy-symptoms-and-need-for-symptom-relief-medication-in-adults-and-children-in-pivotal-phase-iii\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20131109005037r1&amp;sid=hq1sf1&amp;distro=nx","datePublished":"2013-11-09T12:00:00+00:00","dateModified":"2023-03-22T04:04:32+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-grass-sublingual-allergy-immunotherapy-tablet-significantly-reduced-allergy-symptoms-and-need-for-symptom-relief-medication-in-adults-and-children-in-pivotal-phase-iii\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-grass-sublingual-allergy-immunotherapy-tablet-significantly-reduced-allergy-symptoms-and-need-for-symptom-relief-medication-in-adults-and-children-in-pivotal-phase-iii\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-grass-sublingual-allergy-immunotherapy-tablet-significantly-reduced-allergy-symptoms-and-need-for-symptom-relief-medication-in-adults-and-children-in-pivotal-phase-iii\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20131109005037r1&amp;sid=hq1sf1&amp;distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20131109005037r1&amp;sid=hq1sf1&amp;distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-grass-sublingual-allergy-immunotherapy-tablet-significantly-reduced-allergy-symptoms-and-need-for-symptom-relief-medication-in-adults-and-children-in-pivotal-phase-iii\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck\u2019s Investigational Grass Sublingual Allergy Immunotherapy Tablet Significantly Reduced Allergy Symptoms and Need for Symptom-Relief Medication in Adults and Children in Pivotal Phase III Study"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"be68dd0c-b9df-40d9-9c97-50aa398b1d0b","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Mercks-Investigational-Grass-Sublingual-Allergy-Immunotherapy-Tablet-Significantly-Reduced-Allergy-Symptoms-and-Need-for-Symptom-Reli-48716.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742287","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742287\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742287"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742287"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}